John-John Schnog

9PUBLICATIONS
8CO-AUTHORS
Cardiovascular medicine and haematology not elsewhere classifiedMolecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied statistics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Apr 24, 2026
A critical view of the BJH publication on the lack of benefit of second-line daratumumab in patients with functional high-risk multiple myeloma.

|Apr 14, 2026
The Keynote-177 Randomized Controlled Trial of First-line PD-1 Blockade for Microsatellite-High or Mismatch Repair-Deficient Advanced Colorectal Cancer: Potential Consequences of the Cross-Over Trial Design and Related Issues.

S L Gerritse, E van Meerten, A J Duits

|May 29, 2025
Clinical Benefit of Early Daratumumab Use in Multiple Myeloma is Undefined.

Ruben Van Dijck, Zoran Erjavec, John-John B Schnog

|Feb 06, 2025
Pembrolizumab with chemoradiotherapy followed by pembrolizumab for stage III-IVa cervical cancer: is the ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial practice changing?

Bart M F Penninx, Michael J Samson, John-John B Schnog

|Nov 08, 2024
Design issues with lutetium-177 PSMA-617 registration studies that bias the outcome of the experimental arm reflect an increasing misalignment of contemporary oncology trials with true patient benefit.

J B Schnog, A J Duits, M J Samson

|Feb 14, 2024
Pharmaceutical Industry Payments to Medical Oncologists in the Netherlands: Trends and Patterns Provided by an Open-Access Transparency Data Set.

J B Schnog, M J Samson, I Gersenbluth

Pageof 2

Frequent Collaborators

3 joint publications

Ashley J Duits

2 joint publications

Ruben Van Dijck

1 joint publications

M J Samson

1 joint publications

I Gersenbluth